
Drew Moghanaki/X
Aug 14, 2025, 16:44
Drew Moghanaki: The Results from the Phase 3 HARMONi Trial Will be Presented at WCLC25
Drew Moghanaki, Chief Medical Officer at Respirati, shared a post on X:
“UCLA’s Jonathan Goldman is scheduled to take the stage at WCLC25 to present the results from the phase 3 HARMONi study demonstrating the benefit of Ivonescimab in 2L for pts progressing through osimertinib with little to no more side effects!”
More posts featuring Drew Moghanaki on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 6, 2025, 11:37
Sep 6, 2025, 10:21
Sep 6, 2025, 10:00
Sep 6, 2025, 07:12